Threshold Pharma (THLD) – Hot List
-
Threshold Pharma (THLD) Reports Phase 2 Results for Glufosfamide with Gemcitabine; Nephrotoxicity May Be Slightly Higher
-
Threshold Pharmaceuticals (THLD) to Discontinue Development of TH-070 After Phase 2 & 4 Trials Don't Meet Endpoints
-
Back to THLD Stock Lookup